[Voriconazole at Saint Louis Hospital (Paris): Analysis of two-years of compassionate use].
Emmanuelle
E
Papy
Axel
A
Carde
Patricia
P
Ribaud
Pierre
P
Faure
Sophie
S
Touratier
D000208:Acute Disease; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy; D002177:Candidiasis / Q000188:drug therapy; D015331:Cohort Studies; D005670:Fusarium; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D007938:Leukemia / Q000628:therapy; D009181:Mycoses / Q000188:drug therapy* / Q000401:mortality; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole